The Return of a Long-Feared Disease

Polio, a highly infectious disease caused by the poliovirus, primarily affects children under five. It can lead to irreversible paralysis, and in some cases, even death. PNG’s recent outbreak is particularly alarming because it involves vaccine-derived poliovirus type 1 (VDPV1). This occurs when the weakened poliovirus used in the oral polio vaccine (OPV) circulates in under-immunized populations and mutates, regaining its ability to cause paralysis. Global Polio Eradication efforts have largely focused on switching from OPV to inactivated polio vaccine (IPV), which does not carry the same risk of VDPV emergence, but challenges remain in ensuring widespread access and uptake.

Challenges to Immunization in PNG

Low immunization coverage is a major driver of the outbreak. Several factors contribute to this, including geographical challenges – PNG’s rugged terrain and remote islands make it difficult to reach all children with vaccines. Misinformation and vaccine hesitancy also play a role, fueled by rumors and a lack of trust in health authorities. Calls for higher immunisation in PNG on World Polio Day emphasize the urgent need to address these barriers and increase vaccine acceptance.

Australia’s Role in the Response

Australia is playing a crucial role in supporting PNG’s response to the polio outbreak. The Peter Doherty Institute for Infection and Immunity is at the forefront of genomic surveillance, analyzing poliovirus samples to track the spread of the virus and understand its evolution. This information is vital for tailoring vaccination campaigns and implementing effective control measures. Inside Australia’s frontline lab tracking the polio outbreak in Papua New Guinea details the complex work being done to combat the virus.

The Australian government is also providing financial and logistical support to PNG’s vaccination campaigns. These campaigns aim to reach every child with the polio vaccine, regardless of their location. However, sustaining high immunization coverage requires a long-term commitment and ongoing investment.

What lasting impact will this outbreak have on public health infrastructure in PNG? And how can international collaboration be strengthened to prevent similar outbreaks in other vulnerable regions?

Frequently Asked Questions About Polio in PNG

• What is vaccine-derived poliovirus (VDPV)?

  VDPV emerges when the weakened poliovirus in the oral polio vaccine (OPV) circulates for a long time in under-immunized populations and mutates, regaining the ability to cause paralysis.

• Why is PNG experiencing a polio outbreak now?

  Low immunization coverage, geographical challenges, and the circulation of vaccine-derived poliovirus are the primary reasons for the current outbreak in Papua New Guinea.

• How is Australia helping PNG combat polio?

  Australia is providing genomic surveillance through the Peter Doherty Institute, as well as financial and logistical support for vaccination campaigns.

• Is the polio vaccine safe?

  Yes, both the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV) are safe and effective. The benefits of vaccination far outweigh the risks.

• What are the symptoms of polio?

  Most people infected with poliovirus experience no symptoms. However, some may develop flu-like symptoms, such as fever, fatigue, and headache. In a small percentage of cases, polio can cause irreversible paralysis.